Findings

What do systematic reviews say?

10 questions · 10 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 10 · 100%Moderate 0 · 0%High 0 · 0%

Sulthiame vs levetiracetam

Adverse effects (cardiac) · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in adverse effects (cardiac) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 2.87 [0.12, 66.75]
1 study · 43 participants
Low

Sulthiame vs levetiracetam

Gastrointestinal adverse events · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in adverse effects (gastrointestinal) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 0.76 [0.37, 1.56]
1 study · 43 participants
Low

Sulthiame vs levetiracetam

Adverse effects (bones and muscles) · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in adverse effects (bones and muscles) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 0.95 [0.27, 3.33]
1 study · 43 participants
Low

Sulthiame vs levetiracetam

Adverse effects (others) · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in adverse effects (others) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 1.19 [0.37, 3.85]
1 study · 43 participants
Low

Sulthiame vs levetiracetam

Treatment withdrawal · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in treatment withdrawal compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 0.32 [0.1, 1.03]
1 study · 43 participants
Low

Sulthiame vs levetiracetam

Seizure freedom · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in seizure freedom compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 1.12 [0.88, 1.44]
1 study · 43 participants
Low

Sulthiame vs levetiracetam

Adverse effects (general symptoms) · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in adverse effects (general symptoms) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 1.08 [0.76, 1.54]
1 study · 43 participants
Low

Sulthiame vs levetiracetam

Adverse effects (central nervous system) · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in adverse effects (central nervous system) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 1.17 [0.77, 1.79]
1 study · 43 participants
Low

Sulthiame vs levetiracetam

Adverse effects (behaviour) · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in adverse effects (behaviour) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 0.95 [0.59, 1.55]
1 study · 43 participants
Low

Sulthiame vs levetiracetam

Adverse effects (airways) · participants with epilepsy (BECTS)

Sulthiame may leads to higher adverse effects (airways) compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 2.67 [1.17, 6.12]
1 study · 43 participants
Low